Introduction: Co-medication, gene polymorphisms and co-morbidity are main causes for
high variability in expression and function of the CYP3A isoenzymes. Pharmacokinetic …

Previously, we have validated a 4‐drug phenotyping cocktail, the “Cooperstown cocktail,”
using caffeine (cytochrome P450 [CYP] 1A2, N‐acetyltransferase‐2 [NAT2], and xanthine …

Since the development of effective chemotherapy for children with cancer, it has been
recognized that the response of children to apparently identical therapy, both in terms of …

Background: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a
first-and second-line treatment for colorectal cancer. The response to irinotecan is variable …

Aims The primary objectives of the present study were to establish whether there was a
pharmacokinetic or pharmacodynamic interaction between the probe drugs caffeine …

Aim: The CYP3A4* 22 allele was recently reported to be associated with reduced CYP3A4
activity. We investigated the impact of this allele on the metabolism of the CYP3A …

Purpose: To evaluate the effect of naturally occurring variants in genes encoding the
cytochrome P 450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving …

Introduction The clearances of oral and intravenous alfentanil are in vivo probes for
assessing first‐pass and hepatic cytochrome P450 (CYP) 3A activity. Clearance …

Background: Optimal monitoring of vancomycin in children needs evaluation using the
exposure target with area under the curve (AUC) of the serum concentrations versus time …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Schisandra sphenanthera extract
(SchE) and tacrolimus are often co‐administered in treating renal and liver transplant …